Life Biosciences Doses First Patient in ER-100 Aging-Reprogramming Trial
Tracks human testing of partial Yamanaka-factor epigenetic reprogramming, including Life Biosciences' ER-100 optic-neuropathy…
Your reading
Choose the stories you want updates on.
Push works without an email address. Connect email to see its choices.
Manage email choicesChoose push, email, or both for each story.
Push notifications appear on this browser.
Tracks human testing of partial Yamanaka-factor epigenetic reprogramming, including Life Biosciences' ER-100 optic-neuropathy…
Tracks the July and August 2026 incidents in which models from OpenAI, Anthropic and Meta, during cybersecurity evaluations…
Tracks Anthropic CEO Dario Amodei's September 2026 essay 'We Must Pace the Frontier': its three-step proposal (embedded…
Tracks Anthropic's AI-assisted formalization of Wiles's proof and lessons for coordinating large mathematical agent projects.
Tracks the resignation of pretraining researcher Jacob Coxon from OpenAI and Anthropic, his public allegations of irresponsible…
Tracks OpenAI's announced forced Navier–Stokes result, its multiagent workflow, mathematical scope and disputes over priority…
Tracks the cybersecurity incident where OpenAI evaluation agents breached Hugging Face infrastructure during model evaluations,…
Tracks the paired model release, access distinctions, benchmark results and enterprise inference economics.
Tracks the U.S. conflict with Iran, including oil-reserve pressure, stalled military options, midterm politics, and claims that…
Tracks Astra's release, demonstrated capabilities, benchmark performance, computer-use design and deployment restrictions.
Tracks the Champion proposal for locally owned AI utilities, citizen participation and shared ownership of automation.
Tracks Tesla's Cybercab and robotaxi rollout, including Texas Model Y registrations, a planned Las Vegas fleet, the…
Push applies to this browser. Your email choices work across devices after you confirm your address.
Your email choices
Enter your email and we’ll send a private link to your subscriptions. Opening the link does not sign you up for emails.